Figure 5
From: The tetraspanin CD151 marks a unique population of activated human T cells
Effect of ERK and p38 pathway inhibition on CD151 expression in CD4+ T cells. PBMCs from four healthy individuals were treated with the ERK inhibitors (Ulixertinib, ULI or SCH772984, SCH), the p38 inhibitors (Losmapimod, LOS or Doramapimod, DORA), or DMSO as control, and 3 days post treatment analyzed for the expression of CD151 and CD38 using flow cytometric analysis. (a) Representative flow cytometry histogram plots showing the expression of CD151. (b) The effect of each inhibitor on baseline CD151 expression levels in comparison to the inhibitor effect on CD38 expression as determined for four individuals. (c) Representative flow cytometry histogram plots showing the expression of CD151 following anti-CD3/CD28 mAb stimulation in the absence or presence of the indicated inhibitors. (d) The effect of each inhibitor on activation-induced CD151 expression levels analyzed for the expression of CD151 and CD38 using flow cytometric analysis for CD4+ T cells. Due to extensive donor variation regarding CD151 expression levels (baseline MFI range 216–875) data are represented as relative MFI normalized for the CD151 baseline expression in untreated cells.
